Commodore Capital LP
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Commodore Capital LP reported 31 stock positions worth $1.4 billion. Its top holding was Merus (MRUS) at 13.9% of the portfolio, followed by Nuvalent Class A (NUVL, 9.7%) and Enliven Therapeutics (ELVN, 6.8%). Compared with Q4 2024, it opened 4 new positions, sold out of 4, added to 13 and reduced 4. The biggest buy was a new position in Agios Pharmaceuticals (AGIO) and the biggest sale Xenon Pharmaceuticals (XENE, shares −15%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001831942
- Portfolio Value
- $1.4B (Q1 2025)
- SEC Filing
- 0001831942-25-000005 ↗ filed May 15, 2025
Holdings Value
Holdings 31 stocks · $1.4B
| MRUS Merus NV | 13.87% | 4,472,840 | $188.3M | Add +15.4% |
| NUVL Nuvalent Inc. Class A | 9.69% | 1,855,000 | $131.6M | Add +14.4% |
| ELVN Enliven Therapeutics Inc. | 6.78% | 4,675,000 | $92.0M | Add +11.2% |
| SLNO Soleno Therapeutics Inc. | 6.05% | 1,150,000 | $82.2M | Reduce -24.6% |
| XENE Xenon Pharmaceuticals Inc. | 5.75% | 2,325,000 | $78.0M | Reduce -15.2% |
| ALKS Alkermes PLC | 4.74% | 1,950,000 | $64.4M | Reduce -15.2% |
| AGIO Agios Pharmaceuticals Inc. | 4.72% | 2,185,000 | $64.0M | New |
| PCVX Vaxcyte Inc. | 4.59% | 1,650,000 | $62.3M | Add +1.5% |
| VERA Vera Therapeutics Inc. | 4.53% | 2,561,782 | $61.5M | Add +30.8% |
| CLDX Celldex Therapeutics Inc. | 4.28% | 3,200,000 | $58.1M | New |
| SRRK Scholar Rock Holding Corp. | 4.13% | 1,745,000 | $56.1M | Add +83.7% |
| COGT Cogent Biosciences Inc. | 3.93% | 8,892,816 | $53.3M | Add +29.2% |
| VRDN Viridian Therapeutics Inc. | 3.58% | 3,600,000 | $48.5M | Add +50.0% |
| NRIX Nurix Therapeutics Inc. | 3.48% | 3,978,907 | $47.3M | Add +32.6% |
| CNTA Centessa Pharmaceuticals Ltd. | 2.51% | 2,367,578 | $34.0M | Add +6.7% |
| SYRE Spyre Therapeutics Inc. | 2.36% | 1,988,084 | $32.1M | No change |
| PHVS Pharvaris NV | 2.21% | 1,911,433 | $30.0M | No change |
| MIND MEDICINE MINDMED INC | 1.95% | 4,525,000 | $26.5M | Add +5.0% |
| SLDB Solid Biosciences Inc. | 1.59% | 5,825,000 | $21.6M | New |
| DRUG Bright Minds Biosciences Inc. | 1.33% | 500,000 | $18.0M | No change |
| CRDF Cardiff Oncology Inc. | 1.25% | 5,384,616 | $16.9M | No change |
| ORKA Oruka Therapeutics Inc. | 1.07% | 1,419,714 | $14.6M | No change |
| IKT Inhibikase Therapeutics Inc. | 0.86% | 5,344,432 | $11.7M | Reduce -9.8% |
| ORIC Oric Pharmaceuticals Inc. | 0.82% | 2,000,000 | $11.2M | No change |
| APGE Apogee Therapeutics Inc. | 0.80% | 290,000 | $10.8M | No change |
| NGNE Neurogene Inc. | 0.80% | 925,000 | $10.8M | Add +15.6% |
| TYRA Tyra Biosciences Inc. | 0.65% | 950,000 | $8.8M | New |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.57% | 750,000 | $7.7M | No change |
| CELC Celcuity Inc. | 0.52% | 695,650 | $7.0M | Add +73.9% |
| VTGN Vistagen Therapeutics Inc. | 0.29% | 1,575,000 | $3.9M | No change |
| AVTX Avalo Therapeutics Inc. | 0.29% | 483,000 | $3.9M | No change |
Portfolio Sells Q4 2024 → Q1 2025
| XENE Xenon Pharmaceuticals Inc. | Reduce -15.2% | 5.75% | −2.12 |
| ABVX Abivax SA-ADR | Sold out | 0.00% | −0.69 |
| IKT Inhibikase Therapeutics Inc. | Reduce -9.8% | 0.86% | −0.55 |
| BBOT Bridgebio Oncology Therapeut | Sold out | 0.00% | −0.38 |
| THRD Third Harmonic Bio Inc. | Sold out | 0.00% | −0.18 |
| ALKS Alkermes PLC | Reduce -15.2% | 4.74% | −0.10 |
| NKTX Nkarta Inc. | Sold out | 0.00% | −0.06 |
| SLNO Soleno Therapeutics Inc. | Reduce -24.6% | 6.05% | +1.03 |
Portfolio Buys Q4 2024 → Q1 2025
| AGIO Agios Pharmaceuticals Inc. | New | 4.72% | +4.72 |
| CLDX Celldex Therapeutics Inc. | New | 4.28% | +4.28 |
| MRUS Merus NV | Add +15.4% | 13.87% | +1.93 |
| SLDB Solid Biosciences Inc. | New | 1.59% | +1.59 |
| SRRK Scholar Rock Holding Corp. | Add +83.7% | 4.13% | +1.13 |
| TYRA Tyra Biosciences Inc. | New | 0.65% | +0.65 |
| NUVL Nuvalent Inc. Class A | Add +14.4% | 9.69% | +0.39 |
| VRDN Viridian Therapeutics Inc. | Add +50.0% | 3.58% | +0.20 |
| CELC Celcuity Inc. | Add +73.9% | 0.52% | +0.13 |
| COGT Cogent Biosciences Inc. | Add +29.2% | 3.93% | −0.01 |
| ELVN Enliven Therapeutics Inc. | Add +11.2% | 6.78% | −0.15 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +6.7% | 2.51% | −0.21 |
| MIND MEDICINE MINDMED INC | Add +5.0% | 1.95% | −0.25 |
| NGNE Neurogene Inc. | Add +15.6% | 0.80% | −0.54 |
| NRIX Nurix Therapeutics Inc. | Add +32.6% | 3.48% | −0.66 |
| VERA Vera Therapeutics Inc. | Add +30.8% | 4.53% | −1.54 |
| PCVX Vaxcyte Inc. | Add +1.5% | 4.59% | −5.16 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 33 | $1.7B | RLAY, ELVN, ALKS, COGT, AMLX |
| Q1 2026 | 36 | $1.7B | RLAY, ALKS, ELVN, COGT, SYRE |
| Q4 2025 | 33 | $1.5B | RLAY, ALKS, TYRA, XENE, SYRE |
| Q3 2025 | 37 | $2.0B | MRUS, NUVL, XENE, COGT, ELVN |
| Q2 2025 | 33 | $1.4B | MRUS, NUVL, XENE, ELVN, AGIO |
| Q1 2025 | 31 | $1.4B | MRUS, NUVL, ELVN, SLNO, XENE |
| Q4 2024 | 31 | $1.4B | MRUS, PCVX, NUVL, XENE, ELVN |
| Q3 2024 | 36 | $1.6B | MRUS, VERA, XENE, PCVX, ELVN |
| Q2 2024 | 35 | $1.5B | MRUS, NUVL, XENE, PCVX, ELVN |
| Q1 2024 | 39 | $1.5B | MRUS, VERA, NUVL, XENE, SYRE |